treatment
-
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Alzheimer’s & Dementia Care
Study reports Alzheimer’s treatment gains in long-term care
Top-line data emanating from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was linked to significant provider-reported…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting…
Read More » -
Disability Support & Independent Living
FDA Withdraws Approval of Wellcovorin, GSK’s Branded Leucovorin, Amidst Complex History of Autism Treatment Claims
United States regulators have formally withdrawn the Food and Drug Administration’s (FDA) approval for Wellcovorin, the branded version of leucovorin…
Read More » -
Palliative & Hospice Care
Alzheimer’s Disease, Amyloid, and Antibodies: Experts Grapple with Evolving Definitions and Treatment Dilemmas
The landscape of Alzheimer’s disease diagnosis and treatment is undergoing a profound transformation, driven by advancements in understanding the disease’s…
Read More » -
Palliative & Hospice Care
Palliative Care: A Beacon of Hope Amidst the Spectrum of Cancer Treatment
The landscape of cancer treatment often presents patients and their families with a stark dichotomy: the fervent hope for a…
Read More »

